Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,728.50
Bid: 1,727.00
Ask: 1,728.00
Change: 23.50 (1.38%)
Spread: 1.00 (0.058%)
Open: 1,705.00
High: 1,729.50
Low: 1,695.50
Prev. Close: 1,705.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

REFILE-UPDATE 2-Strong sterling knocks FTSE 100 despite trade lull

Thu, 05th Sep 2019 09:29

(Reinstates dropped word 'said' in para 7)

* FTSE 100 down 0.6%, FTSE 250 up 0.2%

* Exporter stocks fall as pound surges

* CYBG tanks on mid-caps

* Online retailer Boohoo jumps after forecast upgrade

* Industrials up on upbeat forecast from European peers

By Muvija M and Indranil Sarkar

Sept 5 (Reuters) - London's FTSE 100 slipped on Thursday as
a surge in sterling pushed exporter stocks lower, missing out on
a global rally led by growing hopes of a resolution to the
U.S.-China trade dispute.

The FTSE 100 slid 0.6%, with multinationals
including spirits company Diageo, pharma giants
AstraZeneca and GlaxoSmithKline slipping about
3% as a strong pound meant the value of their U.S. earnings was
lower.

Sterling recorded its biggest two-day rise in 10 months as
no-deal Brexit worries took a break, after lawmakers voted to
prevent Prime Minister Boris Johnson from taking Britain out of
the European Union without a deal on Oct. 31.

Strength in the local currency lifted the more domestically
focussed mid-cap index by 0.2%, despite a 21% slump in
CYBG to an all-time low. The Yorkshire Bank and Virgin
Money owner said it expected to increase its provision for
legacy payment protection insurance costs.

Stocks trading without dividend entitlement on the day such
as BHP, Glencore and Micro Focus fell
between 1.2%-3%, weighing heavily on the blue-chip index. Micro
Focus is also set to be relegated from the index later this
month.

Meanwhile, indexes on Wall Street and Europe scaled a
one-month high as agreement by China and the United States to
hold high-level trade talks in October spurred hopes that the
trade dispute between the countries would be resolved.

"If one was feeling cynical, Thursday's rally could be used
to illustrate investors' refusal to learn from their past
mistakes, stung time and time again by a pair of superpowers who
never manage to deliver on their trade talk promises," said
Spreadex analyst Connor Campbell.

The FTSE 100 had suffered its only monthly fall this year in
August when trade tensions escalated between the world's largest
economies.

As investors turned to riskier assets on account of renewed
trade hopes and away from safe haven gold, precious metals miner
Fresnillo tumbled nearly 6% and was the steepest faller
on the FTSE 100.

Industrial giants BAE Systems and Rolls-Royce
helped limit the index's fall with gains of 1% each after
French engine maker Safran hiked a profit forecast and
Rafale warplanes maker Dassault Aviation affirmed a
higher net sales target.

Another prominent gainer was turnaround specialist Melrose
which jumped 9% after its first-half profit beat
estimates.

On the mid-cap bourse, specialist media services company
Future Plc surged 10% after upbeat forecast, while
payments solutions provider Network International lost
7.5% as its major shareholder Emirates NBD Bank sold stock at a
discount.

AIM-listed online fashion retailer Boohoo shot up
by 15.1% to a life high after raising its annual revenue growth
forecast and small-cap oil firm EnQuest climbed 7% after
affirming its full-year production view and cutting debt.
(Reporting by Shashwat Awasthi, Muvija M and Indranil Sarkar in
Bengaluru; Editing by Bernard Orr)

More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.